Drug Dosages for Heavy Menstrual Bleeding
For heavy menstrual bleeding, use NSAIDs (ibuprofen or mefenamic acid) for 5-7 days during bleeding, tranexamic acid for 5 days, levonorgestrel-IUS (52 mg device releasing 20 μg/24h), combined oral contraceptives (standard formulations), continuous progestins (norethisterone 0.35 mg daily or medroxyprogesterone acetate 2.5 mg daily), GnRH antagonist combinations with add-back therapy (estradiol/norethindrone), or GnRH agonists with add-back therapy as needed.
First-Line Medical Management
NSAIDs
- Ibuprofen: Use for 5-7 days during bleeding episodes 1, 2
- Mefenamic acid: 5-7 days during bleeding 1
- These reduce menstrual blood loss significantly in most studies and are recommended as initial short-term treatment
Tranexamic Acid
- Dosing: 5 days of treatment 2
- Significantly reduces mean blood loss compared to placebo 1
- Critical caveat: Contraindicated in women with active thromboembolic disease or history/intrinsic risk for thrombosis 1, 3
Hormonal Therapies
Levonorgestrel-Releasing Intrauterine System (LNG-IUS)
- 52 mg device: Releases 20 μg levonorgestrel per 24 hours 4, 5, 6, 7
- Most effective long-term option with 93% reduction in bleeding at 6 months 7
- Provides endometrial protection and contraception simultaneously 4, 5, 8
- 62% of users become amenorrheic by 12 months 6
Combined Oral Contraceptives
- Standard formulations containing estrogen and progestin 9, 2
- No specific dosing provided in guidelines, but standard cyclic regimens (21-24 days active pills, 4-7 day hormone-free interval) 1
- For extended/continuous use: can take 3-4 day hormone-free interval if breakthrough bleeding occurs (not during first 21 days, not more than once monthly) 1, 2
Continuous Progestins
- Norethisterone acetate: 0.35 mg daily 10
- Medroxyprogesterone acetate (MPA): 2.5 mg daily 10
- Levonorgestrel: 0.075 mg daily 10
- Drospirenone: 3 mg daily 10
Injectable Progestin
- Depot medroxyprogesterone acetate (DMPA): Standard contraceptive dosing 1, 7
- For bleeding during use: NSAIDs 5-7 days or low-dose COCs/estrogen for 10-20 days 1, 2
GnRH Therapy
GnRH Agonists
- Leuprolide acetate: Parenteral administration 9, 11
- Reduces tumor volume and bleeding symptoms
- Important limitation: Initial "flare" effect can precipitate heavy bleeding 11
- Requires add-back therapy to mitigate hypoestrogenic effects
GnRH Antagonists
- Oral formulations (elagolix, linzagolix, relugolix) 9, 11
- More favorable than agonists—no flare effect 11
- Approved for long-term treatment of leiomyoma-related heavy menstrual bleeding
Add-Back Therapy
- Estradiol/norethindrone combination: Used with GnRH antagonists 9, 11
- Estradiol/progestin: Low doses to mitigate hypoestrogenic symptoms (headaches, hot flushes, bone loss) 9
- FDA-approved for fibroid-related heavy menstrual bleeding when combined with GnRH therapy 9
Treatment Algorithm
Step 1: Start with NSAIDs (ibuprofen or mefenamic acid) for 5-7 days during bleeding if no contraindications 1, 2
Step 2: If NSAIDs insufficient, add tranexamic acid for 5 days (if no thrombotic risk) 1, 2
Step 3: For ongoing management, choose based on contraceptive needs and patient preference:
- If contraception desired: LNG-IUS 52 mg (most effective) or combined oral contraceptives 7, 8
- If contraception not needed: Continuous progestins or cyclic progestins 10
Step 4: For refractory cases or preoperative optimization:
- GnRH antagonist with add-back therapy (preferred over agonists to avoid flare) 11
- Consider surgical options if medical management fails
Critical Caveats
- Tranexamic acid: Screen for thrombotic risk factors before prescribing 1, 3
- GnRH agonists: Warn about initial flare effect; consider antagonists instead for severe bleeding 11
- LNG-IUS: Expect irregular bleeding first 3-6 months before improvement 1, 6
- Combined hormonal contraceptives: Contraindicated in women with VTE risk factors, especially >40 years 12
- Treatment duration: NSAIDs and tranexamic acid are short-term (5-7 days); hormonal therapies can be long-term 1, 2
The evidence strongly supports LNG-IUS as the most effective long-term medical management, with the highest reduction in bleeding and best patient compliance 7, 8. For acute management during bleeding episodes, NSAIDs remain first-line with tranexamic acid as adjunct therapy in appropriate candidates 1, 2.